MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Startup

09/152021

Clinical trials show promise for Innocell cancer vaccine

PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient.

Read more
09/092021

New cell therapy battles bacterial infections

For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.

Read more
09/032021

New approach has potential to cure pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition.  Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH.

Read more
09/032021

New compound inhibits pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%.

Read more
09/032021

Vasculonics develops new therapy for acute kidney and chronic diabetic kidney disease with clinical candidates

Vasculonics is an Indiana-based biotech formed out of technology licensed from Indiana University.

Read more
08/112021

Small molecule shows first-in-human MoA for salivary gland cancers

SVC112 is a late-preclinical stage asset with potent single agent activity in genetically-defined models of salivary gland cancer, a neglected and orphan disease with no approved targeted or immunotherapy agents.

Read more
06/152021

ProGel delivers meds for long-term local effect

ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones.  Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.

Read more

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights

An error has occured.